Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: john who wrote (82002)	3/16/2001 12:07:44 PM
From: Jim Bishop	Read Replies (2) \| Respond to of 150070

UNVC Major Initiative by GlaxoSmithKline Biologicals Will Save Even More Lives with UNIVEC Auto-Disable Syringe Which Prevents Re-Use FARMINGDALE, N.Y., Mar 16, 2001 (BUSINESS WIRE) -- The Farmingdale-based UNIVEC, Inc. (OTCBB:UNVC), today applauded GlaxoSmithKline Biologicals for a major contribution to international public health. Starting in March 2001, GlaxoSmithKline (GSK) Biologicals will use the Univec Auto-Disable Syringes with all vials of liquid pediatric vaccines delivered to developing countries and emerging markets. GlaxoSmithKline Biologicals is the first vaccine manufacturer to take this initiative, which will save lives and prevent illness by further helping to stem the spread of infections such as hepatitis B or HIV (the AIDS virus) through the re-use of contaminated syringes. The auto-disable syringes, developed and manufactured by UNIVEC will be delivered to developing countries by GSK with all vials of its liquid pediatric vaccines. The Univec design ensures that when the plunger is fully depressed it locks in that position and cannot be pulled back for further use. While standard disposable syringes and needles are now used in nearly half of all immunizations, the practice of re-using them is widespread particularly in developing countries, with the consequent risk of transmitting blood-borne diseases from vaccine to vaccine. It is now WHO-UNICEF policy that the A-D syringe is the equipment of choice for administering vaccines, both in routine immunization and in mass vaccination campaigns. Jean Stephenne, President and General Manager GSK Biologicals, said: "At GlaxoSmithKline, as well as supplying safe and effective vaccines, we care about what happens to our products after they leave the company. As part of that continuing concern, we have now become the first vaccine manufacturer to supply auto-disable syringes with all vials of our liquid pediatric vaccines delivered to developing countries. We believe this is a further important contribution to worldwide public health." GSK Biologicals will start supplying all vials of liquid pediatric vaccines with A-D syringes to countries including Africa, the Caribbean, Latin America, Eastern Europe, Middle East, South East and South West Asia and other emerging markets. Located at Rixensart in Belgium, GSK Biologicals specialize in vaccine research, development and production. It is part of GlaxoSmithKline, one of the world's leading pharmaceutical and healthcare companies. GSK Biologicals employs more than 900 research scientists in its quest for new vaccines. They are involved in developing and clinically testing more cost-effective and convenient products to prevent the infections, which cause serious worldwide medical problems. In 2000, the company distributed over 1.1 billion doses of vaccines to 177 countries, an average of 35 doses a second. GlaxoSmithKline (NYSE: GSK) -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. UNIVEC is a world leader in auto-disable syringes and is leading the global movement for a conversion to auto-disable syringes from traditional multi-use syringes. Traditional multi-use disposable syringes are acknowledged by the World Health Organization to be responsible for the spread of disease to millions of people each year. Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the company's Securities and Exchange filings under "Risk Factors," including risks relating to dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the company's proposed products (such as marketing, safety, regulatory, patent product liability, supply, competition and other risks.) CONTACT: UNIVEC, Inc. Joel Schoenfeld, 631/777-2000 UNIVEC@UNIVEC.com URL: businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. Copyright (C) 2001 Business Wire. All rights reserved. -0- KEYWORD: NEW YORK INDUSTRY KEYWORD: MEDICAL DEVICES MEDICAL * end of story *